Efficacy of osimertinib in patients with EGFR‐mutation positive non‐small cell lung cancer with malignant pleural effusion

Abstract Background As an epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI), osimertinib has emerged as a standard EGFR‐mutation positive treatment for non‐small cell lung cancer (NSCLC). However, the efficacy of osimertinib for malignant pleural effusion (MPE) remains understudi...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Wiley 2024-02-01
Reeks:	Thoracic Cancer
Onderwerpen:	EGFR malignant pleural effusion non‐small cell lung cancer osimertinib
Online toegang:	https://doi.org/10.1111/1759-7714.15210
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!